The original success of Viagra undeniably reshaped the medication landscape, but investing in companies primarily reliant on off-patent versions presents a complex picture. While early returns were substantial, the end of patents and the rise of less expensive alternatives have diminished market share. Thus, a thorough evaluation of ongoing revenue